Overview

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the rate of therapeutic cure of the combination treatment of MGCD290 and fluconazole as compared to that of fluconazole alone at Test of Cure Visit for patients with moderate to severe vulvovaginal candidiasis.
Phase:
Phase 2
Details
Lead Sponsor:
MethylGene Inc.
Treatments:
Fluconazole